Founded in 2016, Infinovo is a global innovative medical technology company focusing on continuous glucose monitoring (CGM) system technology and diabetes management.
· The company headquarters and production bases are located in Suzhou and Nantong, Jiangsu
· Technology R&D centers in Suzhou
In the past seven years since its establishment, Infinovo has achieved rapid and rapid development. All parameters of Glunovo®CGM series products have reached the global advanced level. As of January 2022, the company's products have expanded into more than 30 overseas countries and regions.
【Technical advantages】
We have established a global R&D team and mastered the three core leading technologies of continuous glucose monitoring (CGM): regulatory membrane system, protease recombination technology and algorithm technology, and we are able to achieve large-scale mass production. Moreover, our product’s performance is comparable to world-class companies in terms of monitoring time, anti-drug response, accuracy, and waterproofing.
In the future, Infinovo will focus on the breakthrough research in semi-permeable membrane materials, electronic media technology, glucose prediction algorithm, data mining and interaction, product structure, product system and closed-loop system, and strive to achieve world’s leading product technology.
【management team】
The management has been deeply involved in the diabetes field for more than 10 years on average. Our founder has 16 years experience in CGM product research and development. The management has also held management positions in the diabetes business units of internationally renowned companies such as Bayer, BD, Medtronic, Cellnovo, and Sanofi.
【R & D capabilities】
110+ patents have been applied, and many of them have entered the PCT.
Glunovo is a cgm product brand of Infiovo Medical. The data of Glunovo® CGM series products are accurate. Clinical trials show that the mean absolute relative error value (MARD value) has reached the global leading level. The report generated by the system is transmitted to service cloud through the App, so that users can both access visualized reports at web-portal, and share the reports with others through App. This whole process enables diabetic patients and his relative to track and manage glucose easily and scientifically. Enjoy life to the fullest.
Adhering to the corporate values of listening, innovation, focus, and integrity, we will focus on continuous glucose monitoring technology, committed to serving diabetic patients and medical professionals, and become a promoter of I improving diabetes care and management. Normativeness, products, research and services are never compromised, and the most wholehearted commitment to patients, quality, and science is made.
【Brand Concept】
Infinovo logo is inspired by the basic "circle" symbol, representing "globalization". The integrity of the circle also implies infinity, perfection, and the pursuit of the ultimate. The logo’s "in" is taken from the brand's English name infinovo (infi=infinity, novo=innovation), reflecting the primary core value of Infinovo's continuous technological innovation. Each element should have its own life and meaning, visually integrating infinity and innovation. After the integration, the brand has life.
Symbols convey to us a positive, optimistic attitude, as well as the meaning of a free-spirited attitude. The overall upward development trend means that the company will develop infinitely in the future, lead innovation, and continue to thrive.
Infinovo Medical Slogan: INNOVATION FOR DIABETES
Glunovo Slogan：Know more and control more
In September, the company was established
In October, first production base was established in Nantong, Jiangsu
Completed an angel round financing of ¥8 million in November
Completed the construction of the production base in December
In December, the research and development of Glunovo® i2 products was completed, and a small batch production line was established
In July, the A round of financing was completed with ¥10 millions – Zhengxingu
In July Completed Glunovo® GN-I type inspection
In November, the mass production line of sensor probes was completed
In November, the research and development of Glunovo® i3 products was completed, and an overseas sales center was established at Neitherland
In April, we established London Technology R&D Center
In June, Glunovo®GN-I completed NMPA clinical trial
In December, Glunovo® i3 obtained CE certification and ISO certificate
In July, the B round of financing was completed with millions of USD - Xianfeng China
In September, Glunovo®GN-Ⅰ submitted NMPA registration
In December, the products of the four EU countries were officially launched for sale
In February, the Glunovo®GN-2 registration project was launched
In March, Glunovo®p3 products obtained CE certificate
In April, Infinovo completed C round of financing of hundreds of millions of RMB -Taifu, Hillhouse, Yunfeng
In July, the construction of Suzhou Factory in Sangtian Island was started
Oct. Glunovo®GN-I obtained NMPA certification
In December, our continuous glucose monitoring system obtained the medical device production license
Sales exceeded ¥10 million in December/Suzhou factory was put into use
In March, Glunovo®GN-I was officially launched in China
Improve Diabetic Patients’ life at anywhere, anytime
Innnovation for Diabetes
Listening: Active, sincere, patient and complete listening to customers and colleagues, independent analysis, professional judgment and timely and sincere feedback. Innovation: Boldly carry out process innovation, technological innovation, organizational innovation, and business innovation; dare to question, strive to broaden one's knowledge, innovate in real time, and establish company's moat to defend. Focus: Focus on CGM technology, adhere to the spirit of craftsmanship, and make everything perfect; each department uses the strength of the team to make the department's affairs to the extreme, leads the development of CGM products, and becomes a CGM benchmark enterprise. Integrity: resolve conflicts and differences in a rational and objective manner, be equal, open, and fair, adhere to principles, do not use public interests for personal interest, and have clear rewards and punishments policies. To achieve "No sooner said than done, deeds must be right."
Label generation method and device, system for monitoring glucose level
Transmitter and its production method
Analyte concentration data generation method and apparatus, system for monitoring analyte levels
Injection molding method and components of shell with built-in PCB board
Communication method and device, electronic device and readable storage medium
Blood sugar prediction method and device, system for monitoring glucose level
Insulin recommendation method and device, system for monitoring glucose level
Communication method and apparatus for analyte concentration data monitoring system
Transplantation method
Automatic calibration method and apparatus, system for monitoring analyte concentration levels